Celastrol in kidney diseases: From therapeutic duality and toxicity to precision renal targeting

Abstract

Kidney disorders have become a prevalent global public health crisis, accompanied by soaring morbidity and insufficient therapeutic regimens in clinical practice. Celastrol, a biologically active pentacyclic triterpenoid isolated from Tripterygium wilfordii, is well documented to exert powerful anti-inflammatory, antioxidant, and anti-fibrotic bioactivities. A growing body of preclinical data confirms that celastrol yields remarkable renoprotective outcomes in a broad spectrum of renal disease models, encompassing diabetic kidney disease, IgA nephropathy, chronic kidney disease, as well as acute kidney injury. Mechanistically, celastrol alleviates renal inflammatory infiltration, oxidative stress injury, and pathological fibrotic remodeling through the synergistic regulation of pivotal signaling axes, such as PI3K/Akt/NF-κB, p38 MAPK/NF-κB, Nrf2/GPX4, and SIRT1/EZH2/Wnt/β-catenin pathways. However, a narrow therapeutic index and systemic toxicity greatly hinder its clinical translation. To address this, kidney-targeted delivery systems-including nanoparticle-based carriers (e.g., liposomes) and microneedle patches-have been developed to increase renal drug accumulation and reduce off-target toxicity. Further efforts should focus on elucidating context-dependent mechanisms, optimizing carrier design, and advancing clinical trials to fully unlock the therapeutic potential of celastrol against kidney diseases.

Keywords

Celastrol / Targeted drug delivery / Efficacy enhancement / Toxicity reduction / Kidney diseases

References

[1] Francis A, Harhay MN, Ong ACM, Tummalapalli SL, Ortiz A, Fogo AB, et al. Chronic kidney disease and the global public health agenda: An international consensus. Nat Rev Nephrol 2024; 20(7): 473-485.

[2] Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. KDIGO 2024 clinical practice guideline for the evaluation and management of chronic kidney disease. Kidney Int 2024; 105(4S): S117-S314.

[3] Bhadange R, Gaikwad AB. Repurposing the familiar: Future treatment options against chronic kidney disease. J Pharm Pharmacol 2025; 77(6): 715-728.

[4] Lv QW, Zhang W, Shi Q, Zheng WJ, Li X, Chen H, et al. Comparison of Tripterygium wilfordii Hook F with methotrexate in the treatment of active rheumatoid arthritis (TRIFRA): A randomised, controlled clinical trial. Ann Rheum Dis 2015; 74(6): 1078-1086.

[5] Shi J, Li J, Xu Z, Chen L, Luo R, Zhang C, et al. Celastrol: A review of useful strategies overcoming its limitation in anticancer application. Front Pharmacol 2020; 11. doi: 10.3389/fphar.2020.558741.

[6] Al-Tantawy SM, Eraky SM, Eissa LA. Novel therapeutic target for diabetic kidney disease through downregulation of miRNA-192-5p and miRNA-21-5p by celastrol: Implication of autophagy, oxidative stress, and fibrosis. Naunyn Schmiedebergs Arch Pharmacol 2025; 398(6): 6915-6928.

[7] Wu Y, Chen R, Deng D, Wu W, Wang X. Celastrol modulates damage of renal tissues in immunoglobulin A nephropathy via targeting TGase-2/HMGB1 signaling pathway. BMC Nephrol 2025; 26(1): 209. doi: 10.1186/s12882-025-04139-7.

[8] Song J, He GN, Dai L. A comprehensive review on celastrol, triptolide and triptonide: Insights on their pharmacological activity, toxicity, combination therapy, new dosage form and novel drug delivery routes. Biomed Pharmacother 2023; 162. doi: 10.1016/j.biopha.2023.114705.

[9] He P, Sun J, Tan J, Shi YN, Zhang CJ, Zhu N, et al. From physicochemical constraints to clinical prospects of celastrol: Challenges and nano delivery strategies. Int J Nanomedicine 2025; 20: 10907-10931.

[10] Yadav P, Jaswal V, Sharma A, Kashyap D, Tuli HS, Garg VK, et al. Celastrol as a pentacyclic triterpenoid with chemopreventive properties. Pharm Pat Anal 2018; 7(4): 155-167.

[11] Lyu Y, Xu SW, Chen L. Study on extraction technology of celastrol from root bark of Tripterygium wilfordii . Anhui Sci Technol 2011; (9): 38-39.

[12] Zhang KL, Tian CK, Wang SS, Wu ZB. Research progress on extraction, isolation and pharmacological activity of celastrol. Shandong Chem Ind 2024; 53(8): 129-131, 135.

[13] Liu YL, Lindert S, Zhu W, Wang K, McCammon JA, Oldfield E. Taxodione and arenarone inhibit farnesyl diphosphate synthase by binding to the isopentenyl diphosphate site. Proc Natl Acad Sci U S A 2014; 111(25): E2530-E2539.

[14] Liu J, Lee J, Salazar Hernandez MA, Mazitschek R, Ozcan U. Treatment of obesity with celastrol. Cell 2015; 161(5): 999-1011.

[15] Zhao PD, Guo YY, Ren XG, Zhang JW, Zhai WS. Mechanism of Tripterygium wilfordii and its active components in treating diabetic kidney disease: A review . Chin J Exp Tradit Med Form 2026; 32(7): 352-362.

[16] Zhang K, Jordan PM, Pace S, Hofstetter RK, Werner M, Chen X, et al. Modulation of inflammation-related lipid mediator pathways by celastrol during human macrophage polarization. J Inflamm Res 2022; 15: 3285-3304.

[17] Hayden MS, Ghosh S. NF-κB in immunobiology. Cell Res 2011; 21(2): 223-244.

[18] Liu T, Zhang L, Joo D, Sun SC. NF-κB signaling in inflammation. Signal Transduct Target Ther 2017; 2. doi: 10.1038/sigtrans.2017.23.

[19] Li X, Zhao S, Xie J, Li M, Tong S, Ma J, et al. Targeting the NF-κB p65-MMP28 axis: Wogonoside as a novel therapeutic agent for attenuating podocyte injury in diabetic nephropathy. Phytomedicine 2025; 138. doi: 10.1016/j.phymed.2025.156406.

[20] Wu Z, Tan W, Wang C, Lin L, Tian E, Huo B, et al. TAX1BP1 regulates the apoptosis of renal tubular epithelial cells in ischemia/reperfusion injury via the NF-κB/PMAIP1 signaling pathway. Inflamm Res 2025; 74(1). doi: 10.1007/s00011-024-01976-4.

[21] Huang HX, Li WW. Research progress on the mechanism of renal resident cells in lupus nephritis based on NF-κB signaling. Chin J Integr Tradit West Med Pediatr 2025; 17(5): 397-401.

[22] Yang R, Feng X, Zhang J, Chen T, Wang W, Liu Y, et al. Peptide FK2 attenuates inflammation and pro-fibrotic cellular transitions via targeting the IKKβ/NF-κB/TGF-β1 axis in renal fibrosis. Eur J Pharmacol 2026; 1015. doi: 10.1016/j.ejphar.2026.178567.

[23] Shen S, Wang X, Li Z, Zhuang J, Zhang K. Dihydroquercetin/taxifolin inhibits METTL3/m6A/PIM2 expression by suppressing RIPK2 phosphorylation-mediated NF-κB p65 signaling pathway to alleviate renal ischemia-reperfusion injury in mice. Kidney Dis (Basel) 2025; 11(1): 543-559.

[24] Sethi G, Ahn KS, Pandey MK, Aggarwal BB. Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-κB-regulated gene products and TAK1-mediated NF-κB activation. Blood 2007; 109(7): 2727-2735.

[25] Wang X, Abu Bakar MH, Kassim MA, Shariff KA, Mohamad Rosdi MN. Renoprotective mechanisms of celastrol in high glucose-mediated HK-2 cell injury through inhibition of the PI3K/Akt/NF-κB signalling pathway. Biochem Biophys Rep 2025; 41. doi: 10.1016/j.bbrep.2025.101928.

[26] Zhang M, Chen Y, Yang MJ, Fan XR, Xie H, Zhang L, et al. Celastrol attenuates renal injury in diabetic rats via MAPK/NF-κB pathway. Phytother Res 2019; 33(4): 1191-1198.

[27] Younis NS, Ghanim AMH. The protective role of celastrol in renal ischemia-reperfusion injury by activating Nrf2/HO-1, PI3K/AKT signaling pathways, modulating NF-κB signaling pathways, and inhibiting ERK phosphorylation. Cell Biochem Biophys 2022; 80(1): 191-202.

[28] Chu C, He W, Kuang Y, Ren K, Gou X. Celastrol protects kidney against ischemia-reperfusion-induced injury in rats. J Surg Res 2014; 186(1): 398-407.

[29] Kim JE, Lee MH, Nam DH, Song HK, Kang YS, Lee JE, et al. Celastrol, an NF-κB inhibitor, improves insulin resistance and attenuates renal injury in db/db mice. PLoS One 2013; 8(4). doi: 10.1371/journal.pone.0062068.

[30] Wu M, Chen W, Yu X, Ding D, Zhang W, Hua H, et al. Celastrol aggravates LPS-induced inflammation and injuries of liver and kidney in mice. Am J Transl Res 2018; 10(7): 2078-2086.

[31] Zhao J, Liu H, Chen Q, Xia M, Wan L, Yu W, et al. Mechanistic study of celastrol-mediated inhibition of proinflammatory activation of macrophages in IgA nephropathy via down-regulating ECM1. Int J Biol Sci 2024; 20(14): 5731-5746.

[32] Xiang G, Shi K, Wang J. Celastrol alleviates murine lupus nephritis via inducting CD4⁺Foxp3⁺ regulatory T cells . Folia Histochem Cytobiol 2022; 60(3): 237-246.

[33] Zhong M. Research progress on Nrf2-Keap1 antioxidant system. Chin J Public Health 2006; 22(3): 360-362.

[34] Baird L, Llères D, Swift S, Dinkova-Kostova AT. Regulatory flexibility in the Nrf2-mediated stress response is conferred by conformational cycling of the Keap1-Nrf2 protein complex. Proc Natl Acad Sci U S A 2013; 110(38): 15259-15264.

[35] Wilmes A, Crean D, Aydin S, Pfaller W, Jennings P, Leonard MO. Identification and dissection of the Nrf2 mediated oxidative stress pathway in human renal proximal tubule toxicity. Toxicol In Vitro 2011; 25(3): 613-622.

[36] Li T, Wang H, Chang B, Lu H, Yang R, Zhang H, et al. Grape seed proanthocyanidin extract inhibits ferroptosis by activating Nrf2/HO-1 and protects against diabetic kidney disease. PLoS One 2025; 20(12). doi: 10.1371/journal.pone.0336472.

[37] Luo Q, Zhu Z, Wan L. Exploring the protective effect and regulatory mechanism of plumbagin on renal ischemia-reperfusion injury based on the Nrf-2/HO-1 signaling pathway. Transplant Proc 2025; 57(6): 1180-1186.

[38] Qing TL, Yan L, Wang SK, Dai XY, Ren LJ, Zhang JQZ, et al. Celastrol alleviates oxidative stress induced by multi-walled carbon nanotubes through the Keap1/Nrf2/HO-1 signaling pathway. Ecotoxicol Environ Saf 2023; 252. doi: 10.1016/j.ecoenv.2023.114623.

[39] Zhan X, Yan C, Chen Y, Wei X, Xiao J, Deng L, et al. Celastrol antagonizes high glucose-evoked podocyte injury, inflammation and insulin resistance by restoring the HO-1-mediated autophagy pathway. Mol Immunol 2018; 104: 61-68.

[40] Yang X, Chen A, Liang Q, Dong Q, Fu M, Liu X, et al. Up-regulation of heme oxygenase-1 by celastrol alleviates oxidative stress and vascular calcification in chronic kidney disease. Free Radic Biol Med 2021; 172: 530-540.

[41] Duo K, Feng X, Tian X, Wang F, Zhao Y, Yu J, et al. Ferroptosis inhibitors: Mechanisms of action and therapeutic potential. Cell Mol Life Sci 2025; 82(1). doi: 10.1007/s00018-025-05958-5.

[42] Kinowaki Y, Taguchi T, Onishi I, Kirimura S, Kitagawa M, Yamamoto K. Overview of ferroptosis and synthetic lethality strategies. Int J Mol Sci 2021; 22(17). doi: 10.3390/ijms22179271.

[43] Wang W, Chen J, Zhan L, Zou H, Wang L, Guo M, et al. Iron and ferroptosis in kidney disease: Molecular and metabolic mechanisms. Front Immunol 2025; 16. doi: 10.3389/fimmu.2025.1531577.

[44] Pan M, Wang Z, Wang Y, Jiang X, Fan Y, Gong F, et al. Celastrol alleviated acute kidney injury by inhibition of ferroptosis through Nrf2/GPX4 pathway. Biomed Pharmacother 2023; 166. doi: 10.1016/j.biopha.2023.115333.

[45] Tang YW, Xu TJ, Cao JW, Jiang MY, Yang RC, Wan F. Celastrol mitigates diabetic kidney disease by inhibiting ferroptosis via the SIRT1/NRF2/GPX4 pathway. Diabetol Metab Syndr 2026; 18(1): 55. doi: 10.1186/s13098-026-02085-4.

[46] Ma D, Dai T, Wang D, Zhang J, Zeng C, Dai S, et al. Celastrol protects against renal tubular injury in early diabetic kidney disease through modulation of NOX2 and ferroptosis. Int Immunopharmacol 2026; 177. doi: 10.1016/j.intimp.2026.116533.

[47] Luo M, Xu Q, Sun Y, He N, Wen Z, Wang Z, et al. Co-chaperone P23 inhibits ferroptosis in sepsis-associated acute kidney injury by regulating GPX4 stability. Shock 2025; 64(2): 254-264.

[48] Nie Y, Fu C, Zhang H, Zhang M, Xie H, Tong X, et al. Celastrol slows the progression of early diabetic nephropathy in rats via the PI3K/AKT pathway. BMC Complement Med Ther 2020; 20(1): 321. doi: 10.1186/s12906-020-03050-y.

[49] Tang YW, Yang RC, Wan F, Tang XL, Zhang HQ, Lin Y. Celastrol attenuates renal injury in 5/6 nephrectomized rats via inhibiting epithelial-mesenchymal transition and transforming growth factor-β1/Smad3 pathway. Exp Biol Med (Maywood) 2022; 247(21): 1947-1955.

[50] Xu C, Wu Z. The effect of tripterine in prevention of glomerulosclerosis in lupus nephritis mice. Zhonghua Nei Ke Za Zhi 2002; 41(5): 317-321.

[51] Tang M, Cao X, Zhang K, Li Y, Zheng QY, Li GQ, et al. Celastrol alleviates renal fibrosis by upregulating cannabinoid receptor 2 expression. Cell Death Dis 2018; 9(6): 601.

[52] Zhang Y, Sun Z, Meng W, Lei S, Sun J, Tang Y, et al. Celastrol attenuates diabetic kidney disease progression by repressing senescence of renal tubular epithelial cells. Front Aging 2025; 6. doi: 10.3389/fragi.2025.1657947.

[53] Tang Y, Wan F, Tang X, Lin Y, Zhang H, Cao J, et al. Celastrol attenuates diabetic nephropathy by upregulating SIRT1-mediated inhibition of EZH2-related Wnt/β-catenin signaling. Int Immunopharmacol 2023; 122. doi: 10.1016/j.intimp.2023.110584.

[54] Ma X, Xu L, Alberobello AT, Gavrilova O, Bagattin A, Skarulis M, et al. Celastrol protects against obesity and metabolic dysfunction through activation of a HSF1-PGC1α transcriptional axis. Cell Metab 2015; 22(4): 695-708.

[55] Tang YW, Cao JW, Lu MD, Yang RC, Wan F. Celastrol, a bioactive compound from Tripterygium wilfordii, exerts renoprotective effects by modulating the gut-kidney axis and PPAR signaling in a mouse model of diabetic kidney disease. Asian Pac J Trop Biomed 2025; 15(9): 353-364.

[56] Wang X, Abu Bakar MH, Kassim MA, Shariff KA, An L, Qin Y. Celastrol protects against diabetic nephropathy by modulating immune-related pathways: A bioinformatics and experimental validation. Am J Transl Res 2025; 17(4): 2467-2483.

[57] Zhao J, Liu H, Xia M, Chen Q, Wan L, Leng B, et al. Network pharmacology and experimental validation to explore that celastrol targeting PTEN is the potential mechanism of Tripterygium wilfordii (Lév.) Hutch against IgA nephropathy . Drug Des Devel Ther 2023; 17: 887-900.

[58] Shao G, Zhu S, Yang B. Applications of herbal medicine to treat autosomal dominant polycystic kidney disease. Front Pharmacol 2021; 12. doi: 10.3389/fphar.2021.629848.

[59] Booij TH, Leonhard WN, Bange H, Yan K, Fokkelman M, Plugge AJ, et al. In vitro 3D phenotypic drug screen identifies celastrol as an effective in vivo inhibitor of polycystic kidney disease. J Mol Cell Biol 2020; 12(8): 644-653.

[60] Chang MY, Hsieh CY, Lin CY, Chen TD, Yang HY, Chen KH, et al. Effect of celastrol on the progression of polycystic kidney disease in a Pkd1-deficient mouse model. Life Sci 2018; 212: 70-79.

[61] Shen C, Wang Q, Ye X, Zhou Y, Xing H, Pan C, et al. Celastrol reduces cisplatin-induced nephrotoxicity by downregulating SNORD3A level in kidney organoids derived from human iPSCs. Front Pharmacol 2025; 16. doi: 10.3389/fphar.2025.1464525

[62] Boran T, Gunaydin A, Jannuzzi AT, Ozcagli E, Alpertunga B. Celastrol pretreatment as a therapeutic option against cisplatin-induced nephrotoxicity. Toxicol Res (Camb) 2019; 8(5): 723-730.

[63] Yu X, Meng X, Xu M, Zhang X, Zhang Y, Ding G, et al. Celastrol ameliorates cisplatin nephrotoxicity by inhibiting NF-κB and improving mitochondrial function. EBioMedicine 2018; 36: 266-280.

[64] Ibrahim MM, Osman A, Helal AI, Faheem AM, El-Kattan MAE, Ibrahim I, et al. Celastrol mitigates acetaminophen-induced nephrotoxicity in rats via targeting renal oxidative stress, inflammation, apoptosis with enhancement in aquaporin 1 level. Rep Biochem Mol Biol 2024; 13(2): 204-217.

[65] Nasrullah MZ, Fahmy UA, Abdel-Naim AB, Babekir EY, Alhothaly AH, Elmesilhy AM, et al. Celastrol mitigates colistin-induced renal toxicity in rats via modulating Nrf-2/HO-1 and NF-κB signaling pathways. J Biochem Mol Toxicol 2025; 39(12). doi: 10.1002/jbt.70641.

[66] Albrakati A. Nrf2-mediated mechanistic pathways of celastrol nephroprotection: Disrupting the oxidative-inflammatory-apoptotic axis in cypermethrin toxicity. Front Pharmacol 2025; 16. doi: 10.3389/fphar.2025.1670444.

[67] Liu X, Zhang Q, Wang P, Peng X, An Y, Chen J, et al. Dissection of targeting molecular mechanisms of celastrol-induced nephrotoxicity via a combined deconvolution strategy of chemoproteomics and metabolomics. Int J Biol Sci 2024; 20(12): 4601-4617.

[68] Zheng Y, Ma Y, He P, Yan L, Cao H, Shao F. Phycocyanin/hyaluronic acid microneedle patches loaded with celastrol nanoparticles for synergistic treatment of diabetic nephropathy. ACS Biomater Sci Eng 2025; 11(1): 371-382.

[69] Wu Q, Wang J, Wang Y, Xiang L, Tan Y, Feng J, et al. Targeted delivery of celastrol to glomerular endothelium and podocytes for chronic kidney disease treatment. Nano Res 2022; 15(4): 3556-3568.

[70] Guo L, Luo S, Du Z, Zhou M, Li P, Fu Y, et al. Targeted delivery of celastrol to mesangial cells is effective against mesangioproliferative glomerulonephritis. Nat Commun 2017; 8(1): 878. doi: 10.1038/s41467-017-00834-8.

[71] Pang M, Duan S, Zhao M, Jiao Q, Bai Y, Yu L, et al. Co-delivery of celastrol and lutein with pH sensitive nano micelles for treating acute kidney injury. Toxicol Appl Pharmacol 2022; 450. doi: 10.1016/j.taap.2022.116155.

[72] Li R, Li Y, Zhang J, Liu Q, Wu T, Zhou J, et al. Targeted delivery of celastrol to renal interstitial myofibroblasts using fibronectin-binding liposomes attenuates renal fibrosis and reduces systemic toxicity. J Control Release 2020; 320: 32-44.

[73] Nan S, Che Y, Gong T, Zhang Z, Fu Y. Renal-targeted drug delivery by chitosan oligosaccharide micelles with HSA-enriched protein corona for the treatment of ischemia/reperfusion-induced acute kidney injury. ACS Appl Mater Interfaces 2024; 36(37): 49913-49925.

[74] Xiong X, Feng X, Wei W, Zhu Y, Li M, Sun K. Celastrol-loaded targeted antioxidative nanozyme for improving lipid metabolism and the renal microenvironment in diabetic nephropathy. ACS Appl Mater Interfaces 2025; 17(35): 49272-49285.

[75] Hu X, Jia M, Fu Y, Zhang P, Zhang Z, Lin Q. Novel low-toxic derivative of celastrol maintains protective effect against acute renal injury. ACS Omega 2018; 3(3): 2652-2660.